Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Samick THK Co., Ltd. (004380.KS)
Daegu, KR
Samick THK Co., Ltd., headquartered in Daegu, South Korea, is a prominent manufacturer and vendor of industrial automation equipment. Their extensive product portfolio includes a variety of linear motion systems, such as LM guides, ball screws, actuators, and ball splines. They also offer sophisticated mechatronics and robotic solutions, including Cartesian coordinate robots, speed loaders, precision tables, and linear motors. Furthermore, the company produces a selection of files and rasps, featuring bee, saw, diamond, and iron wire types. Founded in 1960, Samick THK adopted its present name in April 2006, having formerly been known as SAMICK LMS Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Industrial - Machinery: +7.4%-3.6% Q2'25: -27.0% (vs Q2'24)
-
EPS growth Industrial - Machinery: +15.6%+55.5% ★ Q2'25: -4,721.6% (vs Q2'24)
-
FCF margin FCF growth · Industrial - Machinery: +38.2%+2.5% Q2'25: +18.8% (vs Q2'24)
-
EBIT margin Industrial - Machinery: +10.0%+3.5% Q2'25: -54.7% (vs Q2'24)
-
ROIC Industrial - Machinery: +6.8%+2.5% Q2'25: -30.5% (vs Q2'24)
-
Share dilution Industrial - Machinery: +0.0%+0.0% Q2'25: 0.0% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Industrial - Machinery: -0.65×7.06× Q2'25: -1.99× (vs Q2'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex KOSPI 226490.KS | 0.01% | 40.4K | 0.15% |
| 2 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 39.6K | 0.29% |
| 3 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 24.3K | 0.28% |
| 4 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 83.77 | 0.56% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chang-Su Son | Vice-President and Inside Director | — | — |
| Young-Bae Jeon | President and Director | — | — |
| Young-Hwan Jin | Chairperson and Chief Executive Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 004380.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
